Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
101 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Thrombocytopenia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Thrombocytopenia - Pipeline Review, H2 2014', provides an overview of the Thrombocytopenia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Thrombocytopenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Thrombocytopenia Overview 9 Therapeutics Development 10 Pipeline Products for Thrombocytopenia - Overview 10 Pipeline Products for Thrombocytopenia - Comparative Analysis 11 Thrombocytopenia - Therapeutics under Development by Companies 12 Thrombocytopenia - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Thrombocytopenia - Products under Development by Companies 17 Thrombocytopenia - Companies Involved in Therapeutics Development 18 Shionogi & Co., Ltd. 18 GlaxoSmithKline plc 19 BioLineRx, Ltd. 20 Eisai Co., Ltd. 21 Octapharma AG 22 Bayer AG 23 Portola Pharmaceuticals, Inc. 24 Uni-Bio Science Group Ltd. 25 Cellerant Therapeutics, Inc. 26 Bolder Biotechnology, Inc. 27 ViroMed Co., Ltd. 28 aTyr Pharma, Inc. 29 Neumedicines Inc. 30 Tarix Pharmaceuticals LTD. 31 STATegics, Inc. 32 Prophylix Pharma AS 33 InvivoGen Therapeutics 34 Myelo Therapeutics GmbH 35 Thrombocytopenia - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 rivaroxaban - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 immune globulin (human) - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 VM-501 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 UNI-rhIL-11 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 NL-201 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 eltrombopag olamine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 lusutrombopag - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 avatrombopag - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BBT-030 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 BBT-045 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 NMIL-121 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 PEG-VM501 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 TXA-302 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Tmax - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Gene Therapy for Chemotherapy-Induced Thrombocytopenia - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 BL-8040 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 STST-4 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 CLT-009 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 PRT-060318 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Myelo-001 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Human Platelet Antigen-1a Immunoglobulin - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Thrombocytopenia - Recent Pipeline Updates 76 Thrombocytopenia - Dormant Projects 92 Thrombocytopenia - Discontinued Products 93 Thrombocytopenia - Product Development Milestones 94 Featured News & Press Releases 94 Jun 13, 2014: Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag(Promacta/Revolade) in Pediatric Patients with Chronic Immune Thrombocytopenia 94 Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan 94 Sep 24, 2013: Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia 95 Aug 05, 2013: BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia 95 Jul 26, 2013: Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE in Thrombocytopenia Associated with Chronic Hepatitis C Infection 96 Apr 04, 2013: New therapeutic option for immunocompromised patients in Canada 97 Nov 19, 2012: GlaxoSmithKline's Promacta Receives FDA Approval For Treatment Of Thrombocytopenia 97 Oct 08, 2012: Cellerant Receives $1.6m SBIR Contract Funding To Develop CLT-009 For Treatment Of Thrombocytopenia 98 Aug 28, 2012: Bolder BioTechnology Announces Publication Of Data Demonstrating Utility Of Company's Long-Acting IL-11 Analog To Prevent Renal Ischemia Reperfusion Injury 99 Jul 25, 2012: Ligand Partner GlaxoSmithKline Announces Priority Review For Supplemental New Drug Application For Promacta 99 Appendix 100 Methodology 100 Coverage 100 Secondary Research 100 Primary Research 100 Expert Panel Validation 100 Contact Us 101 Disclaimer 101
List of Tables Number of Products under Development for Thrombocytopenia, H2 2014 10 Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2014 18 Thrombocytopenia - Pipeline by GlaxoSmithKline plc, H2 2014 19 Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2014 20 Thrombocytopenia - Pipeline by Eisai Co., Ltd., H2 2014 21 Thrombocytopenia - Pipeline by Octapharma AG, H2 2014 22 Thrombocytopenia - Pipeline by Bayer AG, H2 2014 23 Thrombocytopenia - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 24 Thrombocytopenia - Pipeline by Uni-Bio Science Group Ltd., H2 2014 25 Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2014 26 Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2014 27 Thrombocytopenia - Pipeline by ViroMed Co., Ltd., H2 2014 28 Thrombocytopenia - Pipeline by aTyr Pharma, Inc., H2 2014 29 Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2014 30 Thrombocytopenia - Pipeline by Tarix Pharmaceuticals LTD., H2 2014 31 Thrombocytopenia - Pipeline by STATegics, Inc., H2 2014 32 Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2014 33 Thrombocytopenia - Pipeline by InvivoGen Therapeutics, H2 2014 34 Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2014 35 Assessment by Monotherapy Products, H2 2014 36 Number of Products by Stage and Target, H2 2014 38 Number of Products by Stage and Mechanism of Action, H2 2014 40 Number of Products by Stage and Route of Administration, H2 2014 42 Number of Products by Stage and Molecule Type, H2 2014 44 Thrombocytopenia Therapeutics - Recent Pipeline Updates, H2 2014 76 Thrombocytopenia - Dormant Projects, H2 2014 92 Thrombocytopenia - Discontinued Products, H2 2014 93
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
